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Introduction: Despite therapeutic advances, many
people with type 1 diabetes are still unable to achieve
optimal glycaemic control, limited by the occurrence of
hypoglycaemia. The objective of the present study is to
determine the effectiveness of day and night home
closed-loop over the medium term compared with
sensor-augmented pump therapy in adults with type 1
diabetes and suboptimal glycaemic control.
Methods and analysis: The study will adopt an
open label, three-centre, multinational, randomised,
two-period crossover study design comparing
automated closed-loop glucose control with sensor
augmented insulin pump therapy. The study will aim
for 30 completed participants. Eligible participants will
be adults (≥18 years) with type 1 diabetes treated with
insulin pump therapy and suboptimal glycaemic
control (glycated haemoglobin (HbA1c) ≥7.5%
(58 mmol/mmol) and ≤10% (86 mmol/mmol)).
Following a 4-week optimisation period, participants
will undergo a 3-month use of automated closed-loop
insulin delivery and sensor-augmented pump therapy,
with a 4–6 week washout period in between. The order
of the interventions will be random. All analysis will be
conducted on an intention to treat basis. The primary
outcome is the time spent in the target glucose range
from 3.9 to 10.0 mmol/L based on continuous glucose
monitoring levels during the 3 months free living
phase. Secondary outcomes include HbA1c changes;
mean glucose and time spent above and below target
glucose levels. Further, participants will be invited at
baseline, midpoint and study end to participate in
semistructured interviews and complete questionnaires
to explore usability and acceptance of the technology,
impact on quality of life and fear of hypoglycaemia.
Ethics and dissemination: Ethical approval has
been obtained at all sites. Before screening, all
participants will be provided with oral and written
information about the trial. The study will be
disseminated by peer-review publications and
conference presentations.
Trial registration number: NCT01961622
(ClinicalTrials.gov).
INTRODUCTION
Type 1 diabetes mellitus (T1D) is charac-
terised by an absolute deﬁciency of insulin
caused by immunologically-mediated damage
to the β cells in the pancreas and raised
blood glucose levels. It is one of the com-
monest endocrine and metabolic conditions
in children and adults. It is estimated that
approximately 285 million adults (5–15%
T1D) and 480 000 children (95% T1D)
Strengths and limitations of this study
▸ The study is a three-centre, multinational, rando-
mised, two-period crossover study comparing
automated closed-loop glucose control with
sensor augmented insulin pump therapy.
▸ The study duration is 3 months and is the longest
day and night closed-loop study under complete
free living conditions to be conducted.
▸ All participants will undergo a period of struc-
tured treatment optimisation prior to the study
intervention and receive equal attention from
study team during each study arm.
▸ Psychosocial evaluation using semistructured
interviews and validated questionnaires will be
conducted to determine the acceptability of inter-
vention, quality of life, diabetes self-management
and fear of hypoglycaemia.
▸ The study is open label and aim for 30 com-
pleted participants.
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worldwide suffer from diabetes.1 Recent reports suggest
that the incidence and prevalence of T1D are increasing
in many countries, at least in the under 15-year age
group with the predicted number of new cases of child-
hood diabetes in Europe increasing to 24 400 in 2020
from 15 000 in 2005.2 3
Despite the rapid advancements in insulin pump tech-
nology and the ongoing development of more physio-
logical insulin preparations, achieving optimal glycaemic
control while avoiding hypoglycaemia4 remains a chal-
lenge for many people with T1D.5 6 The emergence of
continuous glucose monitoring (CGM) over the last
decade, which enables users to view real-time interstitial
glucose readings and receive alarms for impending
hypoglycaemia or hyperglycaemia, thus facilitating
appropriate changes in insulin therapy, is a major step
towards improved diabetes monitoring. Several recent
studies have shown a clinical beneﬁt of CGM on reduc-
tion of glycated haemoglobin (HbA1c)7–10 and the
burden of hypoglycaemia11 12 in those using the device
at least 6 of 7 days. The combination of real-time CGM
with insulin pump therapy (sensor augmented insulin
pump therapy) with the ability to temporarily suspend
insulin delivery at preset glucose levels (threshold based
pump suspension) has also shown to reduce the burden
of hypoglycaemia.13 14
The development of a closed-loop system that com-
bines glucose monitoring with computer-based algo-
rithm dictated insulin delivery, may provide further
improvements in glycaemic control while reducing hypo-
glycaemia and represents a realistic treatment option for
people with T1Ds.15 Closed-loop differs from conven-
tional pump therapy, characterised by preprogrammed
basal delivery, through the use of a control algorithm
which directs subcutaneous insulin delivery according to
sensor glucose levels. The role of the control algorithm
is to translate, in real-time, the information it receives
from the glucose sensor and to compute the amount of
insulin to be delivered by the pump.
Several studies have evaluated the safety and efﬁcacy of
closed-loop under laboratory conditions and shown prom-
ising results. These include evaluations using a rando-
mised design by our group in youths,16 17 adults18 and
pregnant women19 and by others using the model
predictive control algorithm,20 21 the proportional-
integral-derivative approach22 23 and the fuzzy logic
controller.24 25 Insulin and glucagon coadministration
have also been evaluated.26–28
In contrast to studies conducted in the clinical
research facility with carefully controlled conditions,
closed-loop at home is exposed to considerably more
varied meal and exercise patterns, and other life-style
modiﬁers. Participants may overestimate or underesti-
mate carbohydrate content and may undertake
unplanned activity and/or exercise. People using insulin
pump therapy are advised to use temporary reductions
or increments of basal insulin delivery to meet these
demands but this requires a degree of planning and
user intuition and interaction. Since closed-loop systems
modulate delivery of insulin in a glucose responsive
fashion,15 they may be able to achieve better glucose
control than preprogrammed basal rates of conventional
pump therapy.
We have recently completed three short-term home
closed-loop studies under free living conditions (table 1).
Two studies evaluated overnight closed-loop glucose
control in adolescents (3 weeks) and adults (4 weeks)
and one study evaluated day and night closed-loop
control in adults (1-week). During both overnight studies,
closed-loop achieved signiﬁcantly better glucose control
than standard insulin pump therapy combined with real
time CGM without increasing the risk of hypoglycaemia29
30 or negatively impacting quality of life or psychosocial
functioning. 31 32 Encouragingly similar beneﬁts were also
seen during fully automated day and night closed-loop
glucose control with better time in target during day and
night time periods.33
Based on promising results from the above three
studies we plan to assess the efﬁcacy, safety, acceptability
and utility of medium term (3 months) day and night
home closed-loop glucose control in adults at the home
setting compared with sensor augmented pump therapy.
METHODS AND ANALYSIS
Overview
The present study is an open-label, three-centre, multi-
national, randomised, two-period crossover study com-
paring automated closed-loop glucose control with
sensor augmented insulin pump therapy. Study partici-
pants will be adults aged 18 years or over with T1D
treated with insulin pump therapy. Two study






Time spent (%) in target
glucose*
p Value ReferenceClosed loop Open loop†
APCam06 3 Overnight Adolescents 64 (45–79) 47 (18–70) <0.001 29
Angela03 4 Overnight Adults 52.6±10.6 39.1±12.8 <0.001 30
AP@home02 1 Day and night Adults 75 (61–79) 62 (53–70) 0.005 33
*Target range 3.9–8 mmol/L for overnight and 3.9–10.0 mmol/L for day and night closed-loop studies.
†Insulin pump therapy combined with real-time continuous glucose monitoring.
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intervention periods will past 3 months each with 4–
6 weeks wash out period. The order of the two interven-
tions will be random. The study will be coordinated
from the Institute of Metabolic Science, University of
Cambridge, UK. The study will aim for 30 completed
participants (10 participants per centre) recruited from:
1. Addenbrooke’s Hospital, Cambridge University
Hospitals NHS Foundation Trust, Cambridge, UK.
2. Proﬁl Institute, Neuss, Germany
3. Medical University of Graz, Graz, Austria
Recruitment will target up to 42 participants (14 parti-
cipants per centre) to allow for dropouts. Methods of
participants’ recruitment will follow well-established
practice at each centre. Written informed consent will
be obtained from all participants before any study
related activities.
Inclusion criteria
1. The participant has T1D as deﬁned by WHO
2. The participant is 18 years of age or older
3. The participant will have been on an insulin pump
for at least 6 months with good knowledge of insulin
self-adjustment including carbohydrate counting
4. The participant is treated with one of the rapid
acting insulin analogues (insulin Aspart, insulin
Lispro or insulin Glulisine)
5. HbA1c ≥7.5% (58 mmol/mmol) and ≤10%
(86 mmol/mmol) based on analysis from central
laboratory or equivalent (only three participants are
allowed between HbA1c ≥7.5% (58 mmol/mmol)
and ≤8.0% (64 mmol/mol) per centre). Recruitment
will aim for equal proportion of participants above
and below HbA1c 8.5% (69 mmol/mmol).
6. The participant is willing to perform regular capil-
lary blood glucose monitoring, with at least six mea-
surements per day
7. The participant is willing to wear closed-loop system
at home and at work place
8. The participant is willing to follow study speciﬁc
instructions
9. The participant is willing to upload pump and CGM
data at regular intervals
10. The participant is willing to restrict alcohol con-
sumption to ≤2 units per day throughout the study
period
11. Female participants of childbearing age should be
on effective contraception and must have a negative
urine human chorionic gonadotrophin pregnancy
test at screening. In addition in Germany, women of
childbearing potential must use a highly effective
method of birth control, which is deﬁned as those
which result in a low failure rate (ie, less than 1%
per year) and must use two independent methods




2. People who are living alone
3. Any other physical or psychological disease or condi-
tion likely to interfere with the normal conduct of
the study and interpretation of the study results
4. Current treatment with drugs known to have signiﬁ-
cant interference with glucose metabolism, such as
systemic corticosteroids, as judged by the investigator
5. Known or suspected allergy against insulin
6. People with clinically signiﬁcant nephropathy
(eGFR <45 mL/min), neuropathy or active retinop-
athy (deﬁned as presence of maculopathy or more
than background diabetic retinopathy changes) as
judged by the investigator
7. Signiﬁcantly reduced hypoglycaemia awareness
(Gold score ≥4 according to Geddes et al34
8. More than one episode of severe hypoglycaemia as
deﬁned by American Diabetes Association35 in pre-
ceding 12 months (severe hypoglycaemia is deﬁned
as an event requiring assistance of another person
to actively administer carbohydrates, glucagon or
take other corrective actions including episodes of
hypoglycaemia severe enough to cause unconscious-
ness, seizures or attendance at hospital)
9. Random C-peptide >100 pmol/L with concomitant
plasma glucose >4 mmol/L (72 mg/dL)
10. Total daily insulin dose ≥2 IU/kg/day
11. Person is pregnant or breast feeding or planning
pregnancy within next 10 months
12. Severe visual impairment
13. Severe hearing impairment
14. People using implanted internal pacemaker
15. Lack of reliable telephone facility for contact
16. People not proﬁcient in English (UK) or German
(Germany and Austria).
Reﬂecting local practice several additional exclusion cri-
teria were applicable to German site. These included
people with positive results on urine drug screen, posi-
tive alcohol breath test, positive hepatitis B surface
antigen, anti-hepatitis C virus antibodies, anti-HIV 1 anti-
bodies, anti-HIV 2 antibodies, people with signiﬁcant
skin conditions, documented allergy to medical adhe-
sives and those with eating disorders.
Study schedule
The study will consist of up to 20 visits or preplanned tele-
phone/email contacts. Two study intervention periods will
past 3 months each with 4–6 weeks wash out period between
them. The order of the two treatments will be random. The
ﬁrst 6 h of each treatment period will be conducted at the
clinical research facility of the respective centre. The study
ﬂow chart is shown in ﬁgure 1. Key activities undertaken
during each study visit are shown in table 2.
Study training
After enrolment, participants will be trained on the use
of study insulin pump (Dana R Diabecare, Sooil, Seoul,
South Korea) and CGM device (FreeStyle Navigator II,
Abbott Diabetes Care, Alameda, California, USA).36 The
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study insulin pump will be programmed with partici-
pant’s usual basal settings as well as usual insulin to
carbohydrate ratios and correction factors. Ability to use
study devices will be formally assessed using competency
assessment and additional training provided as required.
Treatment optimisation period
There will be a minimum of 4-week optimisation period
for all participants. The participant will be invited to
attend the research centre at weekly intervals during this
period. The data from study insulin pump and CGM
device will be downloaded and will be used for treatment
optimisation. The visits will be conducted by a profes-
sional pump educator possibly accompanied by a
member of the study team and will follow a written cur-
riculum. During the optimisation period formal tests will
be undertaken to assess the adequacy of basal and bolus
setup of participants usual insulin pump therapy. At the
end of the optimisation period participant’s compliance
of using the study CGM and study pump over preceding
14 days will be assessed. To proceed with the study partici-
pants need to demonstrate correct use of study insulin
pump including the use of bolus calculator over 90% of
meal boluses and at least 10 days’ worth of CGM data
during past 14 days of the optimisation period.
Randomisation
Eligible participants will be randomised to the order of
the two study interventions using web-based permuted
blocks of four randomisation based on computer-
generated random code with study centre considered as a
factor. Participants will be allocated as they are enrolled.
Figure 1 Study flow chart.
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Home treatment period
At the start of each treatment period participants will be
brieﬂy admitted to the clinical research facility in the
morning. Over 1 h participants will be provided with
relevant training required for safe and effective use of
the study intervention. This will include training on con-
nection and disconnection of the closed-loop system
and switching between closed-loop and usual pump
therapy. Particular attention will be paid to meal bolus
procedure during treatment periods and the use of
study devices during exercise. During closed-loop period
the meal bolus procedure will include entering the
amount of carbohydrates eaten and glucose level via the
user interface of the computer algorithm device (smart-
phone). During sensor augmented pump therapy, parti-
cipants will enter the information directly into the bolus
calculator residing on insulin pump. The method of cal-
culation of the meal bolus is identical between the two
treatment periods and will utilise the bolus calculator of
the study pump and will include a correction insulin
dose for high or low glucose levels. Competency on the
use of study devices will be assessed by the study team.
Only participants who demonstrate competency on use
of study devices will be allowed to continue to the home
study phase. During this visit participants will have a
blood test for HbA1c and will be asked to complete
questionnaires as outlined below.
Participants will be allowed to go home at mid-
afternoon. They will be advised to continue with study
treatment at home over the next 3 months. Participants
will be asked to download the data from the study pump
and CGM device at regular intervals and will be allowed
to drive while using study devices and adhering to usual
precautions and country speciﬁc rules and regulations.
Participants will be advised to discontinue automated
closed-loop insulin delivery and follow their usual
insulin pump therapy for periods of exercise in the ﬁrst
2 weeks of closed-loop use. After ﬁrst 2-week of use by
participants who usually undertake exercise, closed-loop
system may be applied during moderate exercise if prac-
ticable. During the ﬁrst 2 weeks of each study period
each participant will be advised against international
travel. During the rest of study period travel inside
European Economic Area will be allowed while
closed-loop system is in use.
Contact during 3 months home study period
Participants will have identical planned contacts with the
study team during the two treatment periods. This will
include weekly for ﬁrst 2 weeks and monthly for
Table 2 Schedule of study visits
Visit/contact Description
Visit 1 Recruitment visit: consent, HbA1c, baseline bloods, urine pregnancy test, baseline
questionnaires and interviews
Training Visit 2 Insulin pump training Initiation study pump, Competency assessment
Visit 3 CGM training Initiation of study CGM, Competency assessment
Optimisation
(4 weeks)
Visit 4 Review pump and CGM data and optimisation of treatment. Further device training as
required
Visit 5 Review pump and CGM data and optimisation of treatment
Visit 6 Review pump and CGM data and optimisation of treatment
Visit 7 Review pump and CGM data and optimisation of treatment
CL Intervention
(3 months)
Visit 8 CL initiation at research facility, urine pregnancy test, CL training, competency
assessment, HbA1c
Visit 9* Review use of study devices; further optimisation as required
Visit 10* Review pump and CGM data; further optimisation as required
Visit 11* End of first month; review pump and CGM data; further optimisation as required
Visit 12* End of second month; review pump and CGM data; further optimisation as required
Visit 13 End of closed-loop treatment arm (3 months) HbA1c. Complete questionnaires and
optional interviews. Collect algorithm device (optional return of CGM and study
pump)
– Washout period
Visit 14 Optional—collection of CGM and study pump if handed back during visit 13
SAP Intervention
(3 months)
Visit 15 SAP initiation at research facility, urine pregnancy test, SAP training, competency
assessment,—HbA1c
Visit 16* Review use of study devices; further optimisation as required
Visit 17* Review pump and CGM data; further optimisation as required
Visit 18* End of first month; Review pump and CGM data; further optimisation as required
Visit 19* End of second month; Review pump and CGM data; further optimisation as required
Visit 20 End of SAP arm (3 months) HbA1c. Complete questionnaires and optional interviews.
Collect all study devices
*Could be done via phone/e-mail. The order of CL and SAP interventions will be random.
CGM, real-time continuous glucose monitoring; CL, closed loop; HbA1c, glycated haemoglobin; SAP, sensor augmented pump therapy.
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remainder of the study interventions. Except for the
visits at the start and end of each study intervention, all
other visits will be conducted via telephone/email.
Participants will be provided with 24 h telephone help-
line to contact the study team if they encounter any
technical problems.
Closed-loop system
The FlorenceD2A closed-loop system (University of
Cambridge, Cambridge, UK)37 comprises a model pre-
dictive control algorithm residing on a smartphone
(Nexus 4, LG, South Korea), which communicates wire-
lessly with a purpose made translator unit (Triteq,
Hungerford, UK) and the study pump through a
Bluetooth communication protocol (ﬁgure 2). The
CGM receiver is inserted into the translator which trans-
lates a serial USB protocol into a Bluetooth communica-
tion protocol and powers the CGM receiver when USB
communication takes place. The translator uses
rechargeable batteries to supply power.
Every 12 min, the system calculates a new insulin infu-
sion rate which is automatically sent to the study insulin
pump. The calculations utilise a compartment model of
glucose kinetics38 describing the effect of rapid-acting
insulin analogues and the carbohydrate content of
meals on glucose levels.
The control algorithm will be initialised using prepro-
grammed basal insulin delivery downloaded from the
study pump. Additionally, information about participant’s
weight and total daily insulin dose will be entered at
setup. During closed-loop operation, the algorithm
adapts itself to a particular participant. The treat-to-target
control algorithm aims to achieve glucose levels between
5.8 and 7.3 mmol/L and adjusts the actual level depend-
ing on fasting versus postprandial status and the accuracy
of model-based glucose predictions.
The closed-loop system can operate on battery power
over 2–4 days without recharging. The smartphone
uploads data on a server using a 3G/GSM communica-
tion to ease data transfer and downloads data from study
devices during the sensor augmented pump therapy
when the closed-loop control is disabled. The software
residing on the smartphone comprises a bolus wizard,
used during the closed-loop intervention to deliver meal
and correction boluses, The bolus wizard comprises
identical calculation procedures as bolus wizard residing
on the study pump.
The CGM receiver provides hypoglycaemia and hyper-
glycaemia alarms, the insulin pump provides standard
alarms, and the smartphone alerts the user about
aspects related to closed-loop operation such as when
closed loop started, stopped or terminated. The smart-
phone also visualises sensor glucose, insulin delivery,
carbohydrate content and other relevant data.
Safety precautions during closed loop
Participants will be trained to perform a calibration
check before breakfast and evening meal. If sensor
Figure 2 Design of Florence
D2A automated closed-loop
system.
6 Leelarathna L, et al. BMJ Open 2014;4:e006075. doi:10.1136/bmjopen-2014-006075
Open Access
glucose is above ﬁnger-stick glucose by more than
3 mmol/L, the CGM will be recalibrated. These instruc-
tions resulted from an in silico evaluations of hypogly-
caemia and hyperglycaemia risk39 using the validated
Cambridge simulator.40
If sensor glucose becomes unavailable, prepro-
grammed insulin delivery will be automatically restarted
within 30 min or within 1 h in case of other failures. This
limits the risk of insulin underdelivery and overdelivery.39
Safety rules limit maximum insulin infusion and suspend
insulin delivery at sensor glucose at or <4.3 mmol/L or
when sensor glucose is rapidly decreasing.
Participant withdrawal criteria
The following withdrawal criteria will apply:
1. Participant is unable to demonstrate safe use of study
insulin pump and/or CGM during run-in period as
judged by the investigator.
2. Participant is unable to comply with study insulin
pump and/or CGM during run-in period.
3. Participant may terminate participation in the study
at any time without necessarily giving a reason and
without any personal disadvantage.
4. Signiﬁcant protocol violation or non-compliance.
5. Decision by the investigator or the sponsor that ter-
mination is in the participant’s best medical interest
6. Participant becomes pregnant during the study period.
7. Allergic reaction to insulin.
8. If participant cannot be contacted in 4 weeks subject
will be considered lost to follow-up.
Questionnaires and interviews
A mixed methods psychosocial evaluation using semi-
structured interviews and validated questionnaires, will
be conducted to determine the utility of the device in
terms of acceptability of intervention, quality of life, par-
ticipants’ perceptions of impact on lifestyle, diabetes self-
management and fear of hypoglycaemia.
Qualitative methods
Participants will be invited to join three semistructured
telephone interviews conducted by a health psychologist.
Interviews will explore participants’ experiences, their
expectations and feelings at baseline and then at the end
of each phase that is, closed loop and sensor augmented
pump therapy to determine whether the technologies
matched expectations, whether any difﬁculties occurred,
what were the beneﬁts and downsides of living with the
technologies for the duration of the trial and any another
aspects that have arisen as a consequence of participa-
tion. These interviews will be broadly similar to interviews
conducted in our previous closed-loop studies.31
Quantitative methods
Participants will be invited to complete two questionnaires,
the Diabetes Technology Questionnaire and ADDQoL
Questionnaire, at baseline and at the end of each study
arm. The Diabetes Technology Questionnaire is a 30-item
measure of the impact of, and satisfaction with, techno-
logical tools that may be used in the management of
T1D.41 Participants will be asked to rate their agreement
or disagreement with statements regarding the speciﬁc
complement of diabetes technologies (ie, metre, pump,
continuous glucose monitor and closed-loop system).
Items related to ‘current’ satisfaction and impact as well as
‘change’ in satisfaction and impact since the new technol-
ogy was added to the participant’s regimen will be evalu-
ated. The ADDQoL Questionnaire42 consists of two
overview items; one measures generic overall quality of life
and a further 19 items are concerned with the impact of
diabetes on speciﬁc aspects of life. The 19 life domains are
as follows: leisure activities, working life, local or long-
distance journeys, holidays, physical health, family life,
friendships and social life, close personal relationships, sex
life, physical appearance, self-conﬁdence, motivation to
achieve things, people’s reactions, feelings about the
future, ﬁnancial situation, living conditions, dependence
on others, freedom to eat and freedom to drink. These 19
domains ask the respondents to evaluate how their life
would be if they did not have diabetes.
Statistical analysis
All analysis will be conducted on an intention to treat
basis. Data from all randomised participants with or
without protocol violation including dropouts and with-
drawals will be included in the analysis. The respective
values obtained during the 3 months randomised inter-
ventions contrasting the closed-loop system against the
sensor augmented pump therapy will be compared
using a regression model that accounts for period effect.
Residual values from the regression model will be exam-
ined for an approximate normal distribution. If values
are highly skewed a transformation or nonparametric
analyses will be used. Values will be given mean (SD) or
as median (IQR) for each treatment (closed loop or
sensor augmented pump therapy).
Selected CGM outcomes will also be calculated for (1)
day time and (2) night time separately. The day time will
be classiﬁed as between 08:00 and 23:00 h. The night
time will be classiﬁed as between 23:00 until 08:00 h.
Safety analysis will include all available data from all
recruited participants. A 5% signiﬁcance level will be
used to declare statistical signiﬁcance for all comparisons.
The primary end point
The primary outcome measure is time spent with CGM
glucose concentration in the target range (3.9–
10.0 mmol/L) during 3 months home period. The
primary analysis will be the single comparison of the
above outcome between closed loop and control inter-
ventions and no attempt will be made to formally control
the overall type I error rate for the secondary outcomes.
The secondary end points
The following outcomes on the two treatment arms will
be compared:
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1. HbA1c
2. The area under the curve (AUC) below 3.5 mmol/L
based on continuous subcutaneous glucose
monitoring
3. Time spent with CGM glucose levels in hypogly-
caemic range (<3.9 mmol/L).
4. Time spent with CGM glucose levels <3.5 mmol/L.
5. Time spent with CGM glucose levels <2.8 mmol/L.
6. Time spent with CGM glucose levels in hypergly-
caemic range (>10.0 mmol/L).
7. Time spent with CGM glucose levels in signiﬁcant
hyperglycaemic range (>16.7 mmol/L).
8. Mean of CGM glucose levels.
9. 9. Coefﬁcient of variation (CV) of CGM glucose
levels.
10. Low Blood Glucose Index (LBGI) using CGM.
11. Weekly trend in glucose control and insulin delivery
12. Number of nights when sensor glucose was below
3.5 mmol/L for at least 20 min
13. 13. Duration of periods when sensor glucose values
was below 3.5 mmol/L for at least 20 min
14. Total daily insulin dose
15. Total daily bolus insulin dose
16. Total daily basal insulin dose
17. CV of basal insulin delivery
18. Between 24 h period variability: CV of CGM glucose
between 24 h periods (midnight to midnight)
19. Glucose concentration in the target range (3.9–
10.0 mmol/L), and above and below target range
based on adjusted CGM.43
20. Psychosocial functioning
21. Quality of life
During overnight period between 23:00 and 08:00 (9 h)
the following outcomes will be calculated:
▸ Time spent with CGM glucose concentration in the
target range (3.9–8.0 mmol/L)
▸ Mean CGM glucose levels
▸ The AUC below 3.5 mmol/L based on continuous
subcutaneous glucose monitoring
▸ CV of CGM glucose levels
▸ Between night variability: CV of CGM glucose
between nights
▸ Total insulin dose.
During day period between 08:00 to 23:00 (15 h) the fol-
lowing outcomes will be calculated:
▸ Time spent with CGM glucose concentration in the
target range (3.9–10.0 mmol/L)
▸ Mean CGM glucose levels
▸ The AUC below 3.5 mmol/L based on continuous
subcutaneous glucose monitoring
▸ CV of CGM glucose levels
▸ Between day-time variability: CV of CGM glucose
between days
▸ Total insulin dose
Safety analysis
Safety data including number of participants and
number of occurrences of severe hypoglycaemia events
and signiﬁcant ketonaemia (>3.0 mmol/L) with hyper-
glycaemia as well as nature and severity of any other
adverse events (AEs) including serious adverse device
effects (SADEs) and serious AEs (SAEs) will be tabulated
for all subjects, including dropouts and withdrawals, irre-
spective of whether CGM data are available and irre-
spective of whether closed loop was operational.
Utility outcomes during home phase
System performance will be assessed by evaluating:
▸ Total number of hours and percentage of closed-loop
operation
▸ Total number of hours and percentage of CGM
availability
▸ Time between failures (total hours of closed-loop oper-
ation over number of failures (after closed-loop started))
▸ Time between failures due to CGM unavailability
(total hours of closed-loop operation over number of
terminating conditions due to CGM unavailability
after closed loop started)
▸ Time between failures due to pump connectivity
(total hours of closed-loop operation over number of
terminating conditions due to pump connectivity
(after closed loop started))
▸ Time between other failures (total hours of closed-loop
operation over number of terminating conditions due
to other reasons (after closed loop started)).
CGM accuracy at home
CGM accuracy during 3-month home phase against
capillary glucose measurements will be evaluated using
standard measures of numerical and clinical accuracy
including mean and median absolute relative deviation,
bias, International Standardization Organization criteria
and Clarke error grid analysis.44
Exploratory analysis
Per protocol analysis will be conducted to explore the
relationship between usage of study treatments and
study outcomes. Additional analysis will include assess-
ment of study outcomes on weekly/monthly basis, and
contrasting night versus waking hour outcomes and
those with HbA1c above and below 8.5% (69 mmol/
mol). Glucose control during the optimisation period
will also be evaluated.
Interim analysis
No interim analysis will be performed.
Power calculation
Power calculation was based on the anticipated improve-
ments the primary outcome, the time in spent in the
target glucose range (3.9–10.0 mmol/L) during
3 months home stay. Assuming a SD of 18% at baseline
and average improvement of time in target of 10%, 31
participants are required at the desired 80% power and
an α level of 0.05 (two-tailed).45 Above assumptions are
in line with results from our 1-week home closed-loop
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feasibility study.33 To allow for dropouts up to 42 partici-
pants may be recruited aiming for 30 completed partici-
pants. Participants who dropout of the study during
optimisation period and within the ﬁrst 4 weeks of the
ﬁrst intervention will be replaced.
STUDY MANAGEMENT
Data monitoring and ethics committee
An independent Data Monitoring and Ethics Committee
(DMEC) will comprise a chairperson and two experts.
The DMEC will be informed of all SAEs and any
unanticipated adverse device effects/events that occur
during the study. The DMEC will review compiled AE
data at periodic intervals. The DMEC will report to the
Study Management Committee any safety concerns and
recommendations for suspension or early termination of
the investigation. Composition of the DMEC is shown in
online supplementary appendix 1.
Study management committee
A study management committee consisting of the Chief
Investigator, Study Coordinator, and Study Data Manager
will meet quarterly to discuss the operational aspects of
the study. The Principal Clinical Investigators may also
participate. Composition of the study management team
is shown in online supplementary appendix 1.
Study monitoring
The Study Coordinator will ensure that the study is con-
ducted in accordance with ICH GCP standards through
site monitoring visits. A monitoring plan will be written
and agreed prior to randomisation.
Data management
Conﬁdentiality of participant data shall be observed at
all times during the study. Personal details for each par-
ticipant taking part in the research study and linking
them to a unique identiﬁcation number will be held
locally on a study screening log in the Trial Master File
at each of the investigation centres. These details will
not be revealed at any other stage during the study, and
all results will remain anonymous. The study identiﬁca-
tion number will be used on the case report forms and
on all the blood and serum samples that are collected
throughout the study. Names and addresses will not be
used. Collected samples will be stored securely and
locked away. Only researchers directly involved in the
study will have access to the samples.
Electronic data will be stored on password-protected
computers. All paper records will be kept in locked
ﬁling cabinets, in a secure ofﬁce at each of the investiga-
tion centres. Only members of the research team and
collaborating institutions will have password access to
the anonymised electronic data. Only members of the
research teams will have access to the ﬁling cabinet.
Paper copies of the data will be stored for 15 years in
line with the Data Protection Act 1998.
Direct access to the source data will be provided
for monitoring, audits, ethical committee review
and regulatory authority inspections during and after
the study. The fully anonymised data may be shared
with third parties (EU or non-EU based) for the pur-
poses of advancing management and treatment of
diabetes.
Appropriate procedures agreed by the Chief
Investigator and Clinical Principal Investigators will be
put in place for data review, database cleaning and
issuing and resolving data queries.
Indemnity
Indemnity for any harm arising from the conduct of
research will be provided according to local arrange-
ments in respective centre.
▸ Cambridge, UK—National Health Service indemnity
cover will apply for any claims arising from manage-
ment and conduct of research. Any liability arising
from study design will be covered by the clinical trial
insurance policy organised by the University of
Cambridge.
▸ Neuss, Germany—Proﬁl Institute for Metabolic
Research, Neuss, Germany, will provide insurance for
the participants according to local requirements.
▸ Graz, Austria—Participants will be insured according
to Medical Device Law § 47 (StF: BGBl. Nr. 657/
1996, BGBl. I Nr. 143/2009)
ETHICS AND DISSEMINATION
The study has received approval from independent
research ethics committees in UK, Germany and Austria.
In addition the study has undergone a review by regula-
tory authorities in the UK (MHRA), Germany (BfArM)
and Austria (AGES). All participants will be provided
with oral and written information about the trial, includ-
ing the most common AEs, and the procedures involved
in the study before obtaining written informed consent.
The study will be jointly sponsored by the University of
Cambridge and the Cambridge University Hospitals
NHS Foundation Trust, Cambridge, UK. Standard oper-
ating procedures for monitoring and reporting of all
AEs and adverse device events will be in place, including
SAE, SADE and speciﬁc AEs such as severe hypogly-
caemia. The DMEC will be informed of all serious AEs
and any unanticipated adverse device/method effects
that occur during the study and will review compiled AE
data at periodic intervals.
It is expected that screening and recruitment will com-
mence in April/May 2014 and the study will be com-
pleted by summer 2015. The study results will be
disseminated by peer-review publications and conference
presentations.
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